Effect of Brimonidine on rosacea disease
Phase 2
- Conditions
- Rosacea.Rosacea
- Registration Number
- IRCT20161207031288N4
- Lead Sponsor
- Jarfandishan-e Navid-e Salamat (Janus) knowledge-based Company
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 20
Inclusion Criteria
Having rosacea disease
No treatment received in last three months
Exclusion Criteria
More than 5 inflammatory acne lesions
Special forms of rosacea in addition to Dermatosis
Acute Lupus erythematosus
Previous treatment with Brimonidine gel 33%
Seborrheic dermatits
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Severity of lesions according to and Clinician Erythema Assessment (CEA). Timepoint: Before treatment and 4 and 8 weeks later. Method of measurement: Physical exam.
- Secondary Outcome Measures
Name Time Method Severity of lesions according to Patient Self-Assessment (PSA). Timepoint: Before treatment and 4 and 8 weeks later. Method of measurement: Questionnaire.